News

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.
Popular weight-loss drugs like Ozempic and Zepbound have revolutionized how we tackle obesity. But now, emerging reports ...
Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...
The British drug agency is monitoring a possible increase in cases of the disease, although there is no data yet to warrant ...
As obesity management draws awareness and weight-loss injections are launched in India, hospitals are offering customised ...
A PIL has claimed that licences for these drugs were issued without adequate data or India-specific trials and studies, ...
Both Wegovy and Ozempic are semaglutide – a drug that first entered the US market in 2017 as a diabetes medication. It was ...
I was just a baby scientist when I discovered the hormone that made Ozempic possible. I had no idea how life-changing—and ...
Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.
Going on holiday with weight-loss jabs could land you in a lot of trouble as they are banned or regulated in some countries ...
While real-time data on how Indians are responding to these drugs is still emerging, experts say that sustained weight loss ...
Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...